 |
市場調查報告書
商品編碼
2068549
思覺失調症：新型態療法、未滿足的需求和TPP洞察報告，2026年Schizophrenia - Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026 |
||||||
市場概覽
- 預計義大利思覺失調症市場將從 3.04 億美元成長到 3.35 億美元，顯示市場正在逐步擴張。
- 以下因素正在推動市場成長：
- 擴大長效注射藥物的使用
- 擴大治療策略
- 雖然患者人數穩定成長，但更長的治療週期和預防復發的策略支撐了市場規模。
- 新型抗精神病藥物和數位/行為介入的持續創新有望塑造未來的市場動態。
- 未來的成長取決於能夠解決負面症狀、認知障礙和藥物依從性的治療方法。
對思覺失調症新興療法和TPP的見解
Thelansis 的「思覺失調症：新型療法、未滿足的需求和目標產品概況 (TPP) 洞察報告，2026」對該適應症的關鍵新興療法和主要藥物發現機會進行了全面分析，包括新興的競爭格局、未滿足的需求、目標產品概況 (TPP)、臨床試驗設計以及關鍵意見領袖 (KOL) 的見解。
思覺失調症概述
思覺失調症是一種慢性精神障礙，嚴重影響患者的日常生活，其特徵是陽性症狀（幻覺、妄想和言語混亂）和陰性症狀（社交退縮、動力減退和情感淡漠）。其病因複雜，涉及遺傳易感性、環境壓力以及多巴胺、麩胺酸和乙醯膽鹼路徑的功能失調。診斷基於臨床精神病學評估，並採用DSM-5-TR或ICD-11的標準。兩者都強調對症狀嚴重程度進行多維度評估，而非傳統的、統一的臨床亞型分類。治療需要終身的多學科護理，結合心理社會干預和先進的藥物治療。傳統抗精神病藥物主要透過拮抗多巴胺D2受體發揮作用，而現代治療模式則優先使用新一代口服毒蕈鹼受體促效劑（如扎諾美林和托吡銨），以有效調節神經迴路並緩解症狀，同時避免錐體外系症狀或代謝副作用。此外，在病情嚴重加重的情況下，會採取急性期住院治療以確保安全。
主要亮點
- 在美國，診斷率非常高，約有 95% 的病例被確診，這反映出臨床實踐中較高的意識和篩檢水準。
- 大約 77% 的患者正在接受藥物治療（截至 2025 年），這表明診斷和接受治療之間存在很大的差距。
- 在應對對長期功能有重大影響的負面和認知症狀方面，仍然存在未被滿足的需求。
- 治療依從性仍然是一個重大挑戰，也是導致復發率和反覆住院的因素。
- 為了提高藥物依從性並減輕疾病負擔，長效注射抗精神病藥物（LAI）的使用正在增加。
透過對醫生和關鍵意見領袖 (KOL) 的調查所獲得的見解：
- 透過對關鍵意見領袖 (KOL) 的訪談，我們獲得了更深入的見解，從而進一步完善了調查結果。
- 調查問卷將根據客戶的要求進行客製化。
交付成果格式：
- PowerPoint簡報
- MS Excel
主要問題
- 詳細的競爭格局趨勢
- 管道分析
- 符合新興療法條件的患者
- 大公司
- 主要作用機制
- 發布日期預測等。
- 臨床試驗趨勢分析
- 目標患者群
- 試驗終點
- 測試設計
- 受試者招募標準等。
- 未滿足的需求和機遇
- 目前主要療法的有效性
- 未滿足需求的關鍵領域
- 主要未滿足需求的市場規模估算
- 目標產品概況
- 屬性和級別
- 醫生開立的處方
- 預期患者佔有率
- 關鍵意見領袖對領先新興療法的見解
- 意識
- 預期用途/處理線
- 主要未滿足需求得到滿足的程度
- KOL評論
目標國家
- G8
- 美國
- EU5
- 法國
- 德國
- 義大利
- 西班牙
- 英國
- 日本
- 中國
大公司
- LB Pharmaceuticals Inc.
- Vanda Pharmaceuticals
- Novartis Pharmaceuticals
- AbbVie
- Eli Lilly and Company
- Otsuka Pharmaceutical Co., Ltd.
- Anavex Life Sciences Corp.
- Anxo Pharmaceutical Co., Ltd.
- Qilu Pharmaceutical Co., Ltd.
- Spinogenix
- MapLight Therapeutics
- Bristol-Myers Squibb
- Boryung Pharmaceutical Co., Ltd
- Click Therapeutics, Inc.
- Merck Sharp &Dohme LLC
- Hoffmann-La Roche
- Celon Pharma SA
- Boehringer Ingelheim
- ACADIA Pharmaceuticals Inc.
- Janssen-Cilag Ltd.
- Intra-Cellular Therapies, Inc.
- NeuShen Therapeutics
- Newron Pharmaceuticals SPA
- Alto Neuroscience
- Alkermes, Inc.
目錄
第1章：主要調查結果和分析師說明
- 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。
第2章 競爭情勢
- 目前的治療方法
- 重點
- 診斷和治療過程/演算法
- 主要療法概述及關鍵意見領袖見解
- 新興療法
- 重點
- 診斷和治療過程/演算法
- 領先的新興療法—概述和關鍵意見領袖見解
第3章 產品屬性分析
- 重點
- 科學屬性
- 商業性屬性
- 產品定位
第4章：初步調查
- 目前治療狀態
- 主要治療方法與目標患者族群的比較
- 主要特點和優勢
- 未來治療環境
- 當前挑戰
- 未滿足的需求
- 新興療法
- 主要治療方法與目標患者族群的比較
- 主要特點和優勢
- 未來治療前景
- 未滿足的需求和關鍵意見領袖的期望
第5章：未滿足的需求和TPP分析
- 新興療法的主要未滿足需求和未來成就
- TPP分析與KOL預期
第6章 監理與報銷環境
第7章附錄
Schizophrenia Emerging Therapy and TPP Insights
Thelansis's "Schizophrenia Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.
Schizophrenia Overview
Schizophrenia is a chronic, disabling psychiatric disorder characterized by positive symptoms (hallucinations, delusions, disorganized speech) and negative symptoms (social withdrawal, avolition, blunted affect). Its multifactorial etiology involves genetic vulnerability, environmental stressors, and dysregulation of dopamine, glutamate, and acetylcholine pathways. Diagnosis relies on clinical psychiatric assessment using DSM-5-TR or ICD-11 criteria, both of which emphasize dimensional symptom severity rather than historical, rigid clinical subtypes. Management requires lifelong, multidisciplinary care combining psychosocial interventions with advanced pharmacotherapy. While traditional antipsychotics rely on dopamine D2 receptor antagonism, the modern therapeutic paradigm preferentially deploys next-generation oral muscarinic receptor agonists (such as xanomeline-trospium) to effectively modulate circuits and alleviate symptoms without causing extrapyramidal or metabolic side effects, utilizing acute hospitalization to ensure safety during severe exacerbations.
Key Highlights
- In the United States, diagnosis rates are high, with ~95% of cases identified, reflecting strong clinical awareness and screening.
- Approximately 77% of patients receive drug treatment (2025), indicating a notable gap between diagnosis and treatment uptake.
- Persistent unmet need exists in managing negative and cognitive symptoms, which significantly impact long-term functioning.
- Treatment adherence remains a critical challenge, driving relapse rates and repeated hospitalizations.
- Increasing adoption of long-acting injectable antipsychotics (LAIs) to improve compliance and reduce disease burden.
Market Overview
- The Italy schizophrenia market is projected to grow from $304M to $335M, reflecting modest market expansion.
- Market growth is driven by:
- Increased uptake of long-acting injectable therapies
- Expansion of maintenance treatment strategies
- Despite stable patient population growth, market value is supported by chronic treatment duration and relapse prevention strategies.
- Continued innovation in novel antipsychotics and digital/behavioral interventions is expected to shape future market dynamics.
- Future growth will depend on therapies addressing negative symptoms, cognitive deficits, and adherence improvement.
Insights driven by surveys with physician / key opinion leaders:
- Survey findings are corroborated and enriched by insights from interviews with leading KOLs
- Survey is customized based on client requirements
Deliverables format:
- PowerPoint presentation
- MS Excel
Key business questions answered:
- Detailed emerging competitive landscape
- Pipeline analysis
- Target patients for emerging therapies
- Key companies
- Key mechanism of actions
- Launch date estimates, etc.
- Clinical trial landscape analysis
- Target patient segments
- Trial endpoints
- Trial design
- Recruitment criteria, etc.
- Unmet Needs and Opportunities
- Performance of key current therapies
- Top areas of unmet needs
- Opportunity sizing for key unmet needs
- Target Product Profiles
- Attributes and levels
- Physician likelihood of prescribing
- Expected patient shares
- KOL insights on key emerging therapies
- Level of awareness
- Expected use / line of therapy
- Extent to fulfil key unmet needs
- KOL quotes
Countries Covered
- G8
- United States
- EU5
- France
- Germany
- Italy
- Spain
- U.K.
- Japan
- China
Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country
Companies Mentioned
- LB Pharmaceuticals Inc.
- Vanda Pharmaceuticals
- Novartis Pharmaceuticals
- AbbVie
- Eli Lilly and Company
- Otsuka Pharmaceutical Co., Ltd.
- Anavex Life Sciences Corp.
- Anxo Pharmaceutical Co., Ltd.
- Qilu Pharmaceutical Co., Ltd.
- Spinogenix
- MapLight Therapeutics
- Bristol-Myers Squibb
- Boryung Pharmaceutical Co., Ltd
- Click Therapeutics, Inc.
- Merck Sharp & Dohme LLC
- Hoffmann-La Roche
- Celon Pharma SA
- Boehringer Ingelheim
- ACADIA Pharmaceuticals Inc.
- Janssen-Cilag Ltd.
- Intra-Cellular Therapies, Inc.
- NeuShen Therapeutics
- Newron Pharmaceuticals SPA
- Alto Neuroscience
- Alkermes, Inc.
Table of Contents
1. Key Findings and Analyst Commentary
- Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.
2. Competitive Landscape
- Current therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key current therapies - profiles and KOL insights
- Emerging therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key emerging therapies - profiles and KOL insights
3. Product Attribute Analysis
- Key takeaways
- Scientific attributes
- Commercial attributes
- Product positioning
4. Primary Market Research
- Current treatment landscape
- Key therapies vs. focused patient segment
- Key attributes and benefits
- Futures treatment landscape
- Current challenges
- Unmet needs
- Emerging therapies
- Key therapies vs. focused patient segment
- Key attributes and benefits
- Futures treatment landscape
- Unmet needs and KOL expectations
5. Unmet Need and TPP Analysis
- Top unmet needs and future attainment by emerging therapies
- TPP analysis and KOL expectations
